Home Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement
 

Keywords :   


Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement

2013-02-20 13:00:00| Merck.com - Corporate News

Dateline City:  WHITEHOUSE STATION, N.J. & SEOUL, South Korea WHITEHOUSE STATION, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates. Language:  English Contact HTML:  Merck Media Relations:Ronald Rogers, 908-423-6449orMerck Investor Relations:Justin Holko, 908-423-5088orSamsung Bioepis:HongSeok Ji, +82-32-455-6102 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: enter development agreement samsung

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11 (CFI-ZCT1J02)
27.11
27.11QUICKSILVER 8/S 130
27.11
27.11Laurene LaVallis Key To Our Love 7 US
27.11THE SCOPE AFTER DARK LP
27.11
27.11DVD
More »